figur
summar
differ
strategi
drug
deliveri
involv
cpp
cellpenetr
peptid
cpp
har
transloc
wide
rang
molecul
protein
plasmid
peptid
nucleic
acid
short
interf
rna
sirna
liposom
nanoparticl
across
cell
membran
cpp
provid
mean
cellimperm
compound
reach
intracellular
target
convent
cpp
like
tat
deliv
chemotherapeut
agent
cell
specif
herein
lay
one
major
drawback
cpp
lack
cell
specif
limit
hamper
one
promis
applic
cpp
use
deliveri
drug
imag
agent
would
major
relev
abl
target
specif
cell
tissu
healthi
diseas
tissu
contain
organ
diseasespecif
molecular
tag
vasculatur
constitut
vascular
zip
code
system
number
home
peptid
recogn
specif
type
cell
increas
everi
day
advantag
peptid
capac
recogn
specif
phenotyp
thu
home
onto
desir
locat
furthermor
peptid
recogn
target
cell
also
capac
transloc
across
cellular
membran
call
cellpenetratinghom
peptid
tabl
key
featur
peptid
sequenc
hold
target
molecular
address
consequ
offer
great
potenti
vector
drug
deliveri
purpos
show
desir
select
capac
introduc
cargo
specif
cell
target
cellpenetratinghom
peptid
usual
small
longer
amino
acid
nonimmunogen
molecul
show
low
cytotox
cellpenetr
home
peptid
describ
use
vivo
biopan
use
phage
display
peptid
librari
phagedisplay
peptid
librari
method
first
develop
parmley
smith
techniqu
consist
creation
librari
filament
phage
express
random
peptid
nterminu
protein
ie
piii
locat
surfac
viru
phage
display
peptid
librari
screen
biopan
follow
three
gener
screen
method
current
use
biopan
purifi
cell
surfac
membran
protein
b
pan
intact
cell
c
vivo
select
intraven
inject
phagedisplay
librari
bound
phage
elut
amplifi
e
coli
repan
second
time
whole
screen
process
usual
repeat
third
time
order
increas
affin
desir
target
amino
acid
sequenc
peptid
display
phagemid
clone
determin
dna
sequenc
phagedisplay
technolog
allow
detect
differenti
express
molecul
also
differenti
modifi
molecul
addit
techniqu
requir
previou
knowledg
molecular
composit
site
interest
one
first
describ
target
tumor
cell
intern
properti
rgd
argglyasp
peptid
first
report
peptid
recogn
integrin
famili
cellsurfac
receptor
mediat
interact
cell
extracellular
matrix
import
migrat
invas
tumor
cell
integrin
overexpress
neoendotheli
cell
frequent
tumor
cell
sancey
et
al
recent
develop
peptidelik
construct
raftrgd
target
integrin
vitro
vivo
base
regioselect
address
function
templat
raft
cyclodecapeptid
scaffold
develop
mutter
abl
present
four
cyclic
rgd
pentapeptid
motif
figur
raft
cyclic
decapeptid
kkkpgkkkpg
two
orthogon
address
domain
point
either
side
cyclopeptid
backbon
upper
side
raftrgd
peptid
four
copi
cyclic
rgdfk
home
peptid
opposit
face
fluoresc
dye
tetramer
raftrgd
report
tenfold
higher
affin
solubl
receptor
integrin
monomer
crgd
moreov
raftrgd
rapidli
intern
small
vesicl
minut
fact
raftrgd
prove
induc
integrin
intern
observ
intern
enhanc
raftrgd
allow
defin
cpp
research
group
reveal
intern
peptid
clathrinmedi
endocytosi
find
contrast
traffick
rout
follow
integrin
shown
preferenti
use
caveolaedepend
pathway
summari
select
peptid
use
target
tumor
andor
microvasculatur
neovasculatur
home
motif
ngr
isol
peptid
upon
screen
cyclic
peptid
librari
integrin
motif
specif
bind
cell
express
aminopeptidas
n
membranebound
metallopeptidas
multipl
function
regul
variou
hormon
cytokin
protein
degrad
antigen
present
cell
prolifer
cell
migrat
angiogenesi
bare
express
endothelium
normal
blood
vessel
upregul
angiogen
blood
vessel
therefor
ngrcontain
peptid
target
endotheli
cell
pericyt
tumor
also
patholog
condit
inflamm
variou
compound
particl
coupl
ad
synthet
ngr
peptid
order
increas
specif
toward
neovasculatur
first
exampl
ngr
peptid
coupl
anticanc
drug
conjug
cngrc
peptid
doxorubicin
conjug
show
reduc
toxic
improv
efficaci
human
cancer
xenograft
nude
mice
compar
free
doxorubicin
liposom
formul
doxorubicin
target
tumor
coupl
linear
peptid
contain
cngrc
sequenc
anoth
exampl
use
cngrc
deliveri
vector
complex
form
cellpenetr
home
peptid
mitochondri
disrupt
peptid
klaklak
peptid
induc
mitochondri
membran
disrupt
rather
damag
eukaryot
plasma
membran
research
group
succeed
demonstr
apoptot
effect
peptid
construct
breast
carcinoma
xenograft
mice
special
mention
given
ngrtnf
result
conjug
cngrc
peptid
nterminu
tumor
necrosi
factor
tnf
conjug
name
nrgtnf
current
test
phase
ii
clinic
studi
drug
improv
antitumor
activ
administr
picogram
complex
tnf
alon
exert
synergist
antitumor
effect
variou
chemotherapeut
agent
doxorubicin
melphalan
cisplatin
paclitaxel
gemcitabin
modu
operandi
ngrtnf
alter
drugpenetr
barrier
biolog
activ
cytokin
antiangiogen
molecul
endostatin
tumstatin
fragment
improv
coupl
ngr
peptid
target
deliveri
ultralow
dose
picogram
rang
recombin
conjug
tumor
vasculatur
overcom
major
counter
regulatori
mechan
delay
tumor
growth
mice
bieker
et
al
recent
gener
fusion
protein
ttnfngr
extracellular
domain
tissu
factor
truncat
tissu
factor
ttnf
peptid
gngraha
contain
ngr
motif
target
tumor
endotheli
cell
ttnfngr
inhibit
tumor
growth
mice
thrombot
occlus
tumor
vessel
without
major
side
effect
also
report
inhibit
tumor
perfus
first
patient
treat
molecul
exampl
ngrcontain
peptid
provid
good
tool
tumor
target
drug
drug
deliveri
system
peptid
amino
acid
sequenc
deriv
nuclear
protein
high
mobil
group
hmg
protein
highli
conserv
nucleosom
protein
thought
involv
unfold
higherord
chromatin
structur
facilit
transcript
activ
mammalian
gene
author
follow
work
aim
find
marker
share
tumor
vasculatur
endotheli
progenitor
cell
bone
marrow
screen
cdna
librari
display
phage
first
bone
marrow
cell
ex
vivo
tumorbear
mice
vivo
accumul
nuclei
tumor
endotheli
cell
tumor
cell
capac
carri
cargo
nuclei
target
cell
recogn
minor
popul
progenitor
celllik
bone
marrow
cell
also
bind
endotheli
cell
tumor
addit
appear
recogn
varieti
tumor
type
bind
bone
marrow
subpopul
tumor
endotheli
cell
also
system
inject
recogn
minor
popul
healthi
skin
gut
peptid
may
use
target
therapeut
agent
tumor
furthermor
capac
carri
cargo
cell
nucleu
make
promis
tool
drug
target
applic
multipl
anticanc
drug
exert
effect
nucleu
texa
hong
clayman
describ
isol
peptid
tsplnihngqkl
abl
transloc
select
across
cell
membran
human
head
neck
squamou
cell
carcinoma
hnscc
lack
specif
current
approach
treat
hnscc
produc
doselimit
toxic
imped
develop
cur
system
approach
also
signific
improv
surviv
author
studi
consid
potenti
shuttl
drug
kind
tumor
nontox
nonimmunogen
mice
stabl
vivo
moreov
protect
cargo
transit
accumul
effici
within
tumor
h
peptid
may
serv
cancer
therapi
also
tumor
diagnost
agent
imag
agent
may
even
provid
tumorspecif
gene
transfer
approach
novel
peptid
author
propos
intern
receptormedi
howev
limit
receptormedi
endocytosi
specif
adsorpt
endocytosi
cpp
logic
cellpenetr
home
peptid
recogn
kind
molecul
surfac
target
cell
recognit
could
lead
classif
peptid
cpp
kind
peptid
intern
cell
result
interact
cellular
receptor
aim
discuss
tag
peptid
classif
consid
home
cellpenetr
home
peptid
peptid
capac
select
recogn
one
variou
type
cell
transport
kind
cargo
across
cell
membran
cyclic
oligopeptid
ctvalpggyvrvc
specif
bind
glucoseregul
protein
intern
cancer
cell
given
properti
promis
vector
tumor
cellspecif
chemotherapi
discov
late
cellular
protein
induc
glucos
starvat
express
maintain
low
basal
level
major
adult
organ
brain
lung
heart
strongli
induc
tumor
cell
overexpress
intracellular
chaperon
member
heat
shock
protein
famili
provid
protect
cellular
respons
stress
condit
inde
specif
overexpress
cancer
cell
surfac
normal
express
maintain
low
level
upregul
stress
environ
induc
tumor
environ
furthermor
human
cancer
higher
express
relat
greater
patholog
grade
recurr
poor
patient
surviv
breast
liver
prostat
colon
cancer
also
intern
receptormedi
transloc
clathrinmedi
endocytosi
main
mechan
uptak
howev
refer
cpp
author
demonstr
specif
recogn
present
cell
surfac
melanoma
cell
recognit
intern
target
molecul
present
cancer
cell
previous
shown
number
human
primari
cancer
cell
line
overexpress
glucoseregul
protein
assess
drug
deliveri
properti
new
peptid
author
conjug
rang
molecul
distinct
biochem
properti
mechan
action
instanc
chose
amphipath
apoptosisinduc
peptid
klaklak
seen
peptid
exert
action
mitochondri
membran
drug
chosen
hematoporphyrin
photosynthes
activ
lysosom
compart
two
drug
import
cell
presenc
year
later
yoneda
et
al
evalu
conjug
contain
cathepsin
bcleavabl
linker
order
increas
releas
drug
insid
cancer
cell
therebi
facilit
endosom
releas
approach
take
advantag
presenc
cathepsin
b
insid
cell
lysosom
previous
describ
bind
receptor
intern
endosom
pathway
molecul
end
lysosom
compart
cell
research
synthes
conjug
contain
cathepsin
b
cleavabl
linker
valcit
motif
case
highli
stabl
plasma
rapidli
cleavabl
cathepsin
b
drug
chose
well
known
anticanc
agent
taxol
doxorubicin
perform
vivo
assay
vitro
result
ostesarcoma
cell
cell
line
promis
deliveri
system
induc
higher
cell
death
compar
treatment
drug
mitochondri
cytotox
peptid
klaklak
also
coupl
heptapeptid
smsiarl
isol
vivo
phage
display
peptid
librari
specif
target
prostat
vasculatur
peptid
coupl
klaklak
prostat
tissu
destroy
prostatecancerpron
transgen
tramp
transgen
adenocarcinoma
mous
prostat
model
chimer
peptid
postpon
cancer
develop
therebi
suggest
potenti
altern
surgic
approach
use
treat
diseas
azurin
cupredoxin
protein
secret
microorgan
pseudomona
aeruginosa
two
peptid
amino
acid
azurin
lalstaadmqgvvtdgmasgldkdylkpdd
amino
acid
azurin
lglstaadmqgvvtdgmasg
describ
potenti
cpp
peptid
penetr
cancer
cell
without
disrupt
cell
membran
although
still
fulli
understood
uptak
mechan
energydepend
satur
mechan
involv
caveola
golgi
complex
nocodazol
disrupt
caveola
transport
inhibitor
cholesterol
mobil
inhibit
penetr
peptid
author
propos
intern
follow
one
mechan
main
advantag
peptid
preferenti
enter
cancer
cell
author
studi
show
enhanc
intern
rate
sever
tumor
cell
line
vitro
compar
correspond
non
tumor
one
addit
peptid
inhibit
cancer
cell
prolifer
cytostat
cytotox
mechan
azurin
inhibit
growth
sever
human
cancer
line
vitro
togeth
peptid
capabl
preferenti
intern
cancer
cell
also
exert
toxic
effect
therebi
prevent
prolifer
laakkonen
togeth
ruoslahti
cowork
intens
studi
cell
penetr
home
peptid
perform
vivo
biopan
use
phage
display
peptid
librari
identifi
peptid
ligand
vascular
marker
select
express
tumor
endothelium
lymph
vessel
sever
round
biopan
peptid
select
target
specif
site
home
desir
locat
also
capac
intern
target
cell
addit
peptid
also
abl
destroy
target
cell
nineamino
acid
cyclic
peptid
cgnkrtrgc
isol
screen
use
human
breast
cancer
xenograft
like
recogn
marker
present
tumor
cell
tumor
endotheli
cell
furthermor
unlik
vascular
cell
penetr
home
peptid
also
recogn
tumorassoci
lymphat
vessel
recogn
lymphat
vessel
marker
lymphat
vessel
endotheli
hyaluron
acid
transmembran
hyaluron
acid
receptor
podoplanin
glomerular
podocyt
membran
protein
also
vascular
endotheli
growth
factor
receptor
accumul
nucleu
target
cell
primari
tumor
metastat
lesion
intraven
inject
local
preferenti
hypox
area
home
peptid
tumor
typespecif
accumul
tumor
other
addit
tumor
home
transgen
prostat
tumor
tramp
lakkonen
bernasconi
ruoslahti
unpublish
observ
transgen
breast
carcinoma
mmtvpymt
lesser
extent
krib
osteosarcoma
xenograft
melanoma
leukemia
xenograft
describ
extraordinari
cellpenetr
home
peptid
mandatori
stress
capac
trigger
apoptosi
cell
bind
treatment
tumor
cell
caus
cell
death
effect
specif
cell
bind
affect
mechan
kill
cell
remain
unknown
proapoptot
effect
seem
direct
tumor
cell
stress
coloc
tissu
hypoxia
marker
vivo
serum
starvat
enhanc
bind
intern
cultur
tumor
cell
vitro
lymph
vessel
highli
relev
tumor
metastasi
given
destroy
deadli
part
tumor
peptid
could
provid
extraordinari
therapeut
strategi
target
metastasi
earli
stage
process
combin
posit
select
peptidebear
phage
librari
poorli
differenti
colon
carcinoma
cell
neg
select
phage
librari
welldifferenti
colon
carcinoma
cell
kimberli
et
al
describ
nineamino
acid
disulfideconstrain
peptid
cpiedrpmc
rpmrel
peptid
report
target
colon
tumor
tissu
four
patient
without
bind
healthi
colon
tissu
tissu
lung
lung
sarcoma
liver
liver
sarcoma
stomach
furthermor
author
report
efficaci
novel
peptid
transport
mitochondri
toxin
klaklak
tumor
colon
cell
therebi
induc
apoptosi
thu
kill
cell
identif
peptid
select
enter
colon
cancer
cell
promis
develop
new
colon
cancer
diagnost
tool
therapeut
agent
rpmreld
klaklk
colorect
cancer
caus
death
worldwid
per
year
third
common
form
cancer
third
lead
caus
cancerrel
death
western
world
rpmrel
could
lead
develop
new
direct
target
agent
fight
diseas
anoth
exampl
cellpenetr
home
peptid
target
dorsal
root
ganglion
drg
neuron
diseas
affect
neuron
rare
includ
differenti
diagnosi
peripher
sensori
neuropathi
fact
neuropath
pain
common
symptom
variou
disord
although
sever
pharmaceut
agent
use
treat
neuropath
pain
specif
limit
efficaci
drg
neuron
classifi
either
larg
small
j
oi
et
al
isol
three
peptid
recogn
specif
defin
size
drg
neuron
furthermor
peptid
capac
intern
target
cell
therefor
potenti
becom
power
tool
studi
subpopul
drg
neuron
andor
develop
carrier
therapeut
agent
diseas
involv
specif
subtyp
neuron
sequenc
peptid
follow
spgaraf
dgpwrkm
fgqkass
interestingli
intern
mostli
small
neuron
show
prefer
toward
larger
one
experi
show
recogn
distinct
molecul
surfac
small
drg
neuron
result
provid
power
tool
facilit
futur
research
structur
basi
neuron
cellular
subpopul
importantli
gener
new
molecular
deliveri
system
target
drg
neuron
vivo
prolin
uniqu
properti
among
genet
encod
amino
acid
pyrrolidin
ring
confer
molecul
great
rigid
lead
steric
hindranc
peptid
backbon
moreov
conform
amid
bond
stabil
hydrogen
bond
peptid
contain
certain
amount
prolin
polyprolin
adopt
well
defin
secondari
structur
polyprolin
ii
ppii
pure
water
ppii
lefthand
extend
helix
residu
per
turn
contrast
residu
compris
righthand
ppi
form
polyprolin
presenc
aliphat
alcohol
architectur
allow
precis
orient
hydrophil
hydrophob
moieti
along
differ
face
helix
make
structur
solubl
aqueou
media
sever
prolinerich
cpp
describ
date
howev
two
exampl
cation
polyprolin
helic
capac
intern
cell
specif
way
peptid
display
rigid
type
ii
polyprolin
helix
backbon
function
contain
six
cation
moieti
believ
essenti
cell
intern
two
distinct
hydrophob
group
geisler
et
al
assay
intern
two
cpp
seven
cell
line
six
cancer
one
noncancer
describ
select
cell
line
instanc
preferenti
enter
breast
cancer
slightli
intern
also
kb
hela
deriv
connect
tissu
cancer
howev
present
intern
cell
type
effect
intern
kb
cell
lesser
degre
cell
compar
sever
cytotox
assay
also
perform
indic
display
minim
cytotox
cell
line
slightli
toxic
cpp
show
cell
type
prefer
intern
find
exploit
futur
design
direct
drug
deliveri
system
case
peptid
ration
design
obtain
direct
vivo
observ
phage
display
biopan
select
shown
prolinerich
peptid
opinion
valid
vivo
experi
develop
capac
select
desir
target
vivo
context
may
differ
greatli
vitro
observ
describ
phage
display
technolog
revolutionari
tool
discov
new
highli
specif
peptid
techniqu
allow
select
peptid
bind
specif
certain
cell
addit
vivo
phage
display
allow
bind
peptid
true
physiolog
environ
divers
phenotyp
marker
express
screen
new
phage
librari
undoubtedli
lead
discoveri
highli
select
peptid
certain
diseas
even
differ
stage
diseas
furthermor
peptid
would
capac
penetr
cell
therebi
provid
possibl
carri
drug
imag
agent
order
directli
target
affect
area
therebi
prevent
side
effect
caus
nonspecif
drug
current
use
cellpenetr
home
peptid
minim
express
target
drug
deliveri
system
identifi
cellspecif
peptid
cellpenetr
properti
alway
easi
capac
carrier
transloc
across
cell
membran
call
mani
specif
properti
major
drawback
classic
cpp
tat
penetratin
polyarginin
lack
specif
howev
power
nonimmunogen
tool
deliv
cellimperm
drug
cell
cancer
cell
nonspecif
cpp
wide
studi
effici
improv
almost
yearli
new
cpp
continu
emerg
mani
peptid
base
larger
peptid
protein
present
natur
whose
activ
consist
break
cellular
membran
penetr
cell
henc
efficaci
high
essenti
properti
drug
deliveri
system
strong
intern
capac
commonli
clash
high
specif
research
field
make
maximum
use
knowledg
follow
strategi
target
cpp
design
fusion
peptid
contain
cellpenetr
domain
coupl
target
sequenc
like
instanc
home
sequenc
mind
ming
tan
cowork
design
novel
cppbase
cpp
specif
breast
cancer
cell
gene
member
epiderm
growth
factor
receptor
famili
overexpress
breast
cancer
current
therapi
cell
urgent
requir
phenotyp
shown
increas
metastat
potenti
human
breast
cancer
confer
increas
resist
chemotherapeut
agent
activ
activ
stat
protein
signal
transduc
activ
transcript
protein
phosphoryl
stat
transloc
nucleu
bind
statspecif
dna
respons
element
therebi
regul
gene
express
found
activ
activ
may
contribut
transform
tumor
progress
henc
specif
target
breast
cancer
cell
contain
activ
may
inhibit
malign
phenotyp
tat
peptid
one
studi
cpp
wide
studi
conjug
varieti
cargo
transport
cell
studi
ming
tan
et
al
conjug
extracellular
domainbind
peptid
tatderiv
cpp
order
achiev
target
specif
deliveri
synthes
less
effici
version
tat
ygrkkrrqr
call
start
point
induc
cell
specif
new
version
tat
peptid
potent
origin
tat
peptid
consequ
intern
cell
effici
manner
advantag
direct
system
desir
area
unspecif
intern
enter
target
cell
addit
ahnp
acid
anti
peptid
mimet
bind
high
affin
cterminu
tatderiv
peptid
render
transloc
profil
peptid
select
vitro
vivo
also
show
construct
effici
select
deliv
peptid
name
even
select
inhibit
growth
cell
vitro
compar
lowexpress
xenograft
ip
inject
preferenti
accumul
xenograft
led
greater
reduct
prolifer
increas
apoptosi
target
inhibit
tumor
growth
studi
confirm
modular
approach
figur
design
cellspecif
cpp
feasibl
replac
direct
moieti
case
molecular
marker
may
lead
person
therapi
vehicl
peptid
deliv
desir
drug
target
cell
pega
cpgpegagc
cyclic
home
peptid
previous
shown
accumul
breast
vasculatur
well
premalign
breast
tissu
primari
breast
tumor
thought
peptid
bind
aminopeptidas
p
protein
highli
express
membran
breast
tumor
cell
mice
pega
cpp
langel
group
sweden
togeth
myrberg
la
jolla
combin
tumorspecif
home
peptid
pvec
cpp
pvec
lliilrrrirkqahahsk
well
studi
cpp
deriv
murin
sequenc
cell
adhes
molecul
vascular
endotheli
cadherin
amino
acid
cpp
show
good
intern
rate
within
sever
cell
line
combin
two
peptid
show
intern
tumor
cell
vivo
research
evalu
specif
pegapvec
construct
intraven
inject
peptid
label
fluorescein
tumorbear
mice
peptid
detect
tumor
control
tissu
furthermor
conjug
peptid
also
nitrogen
mustard
chlorambucil
cbl
cytotox
agent
act
alkyl
crosslink
dna
produc
higher
efficaci
drug
kill
cell
vitro
cbl
thought
taken
cell
passiv
diffus
combin
drug
describ
chimera
peptid
result
enhanc
activ
drug
compar
activ
administr
alon
effect
suggest
new
specif
peptid
construct
could
use
direct
drug
deliveri
breast
tumor
tissu
two
year
later
chimer
peptid
describ
improv
system
combin
breast
tumor
home
peptid
pvec
cpp
case
home
peptid
creka
identifi
breast
tumor
mmtvpymt
transgen
mice
use
vivo
phage
display
peptid
recogn
clot
plasma
protein
home
select
tumor
blood
vessel
stroma
bind
fibrinlik
structur
show
intern
properti
research
combin
chimer
target
carrier
cytotox
agent
cbl
formul
show
enhanc
intern
properti
compar
previou
one
pegapvec
conveni
synthes
system
improv
characterist
could
also
use
tool
direct
drug
deliveri
exampl
demonstr
combin
two
peptid
achiev
target
deliveri
alreadi
realiti
data
hand
rang
possibl
enorm
conjug
home
peptid
cpp
help
transloc
across
cellular
membran
lead
simpl
effici
usual
noncytotox
drug
deliveri
system
number
home
peptid
discuss
increas
yearli
addit
develop
vivo
phage
display
technolog
could
lead
new
person
way
design
drug
deliveri
system
instanc
laakkonen
ruoslahti
address
new
home
peptid
specif
recogn
tumor
vasculatur
tumor
cell
even
abl
distinguish
differ
stage
cancer
purpos
work
extens
phage
display
peptid
librari
vivo
screen
describ
sever
peptid
interest
tabl
summar
exampl
within
lymphat
vasculatur
sever
tumor
combin
target
peptid
cpp
may
provid
new
approach
design
specif
drug
deliveri
vector
level
specif
achiev
would
select
type
tumorhom
peptid
could
customdesign
patient
treatment
sever
type
cancer
overexpress
certain
surfac
molecul
includ
receptor
breast
cancer
lutein
hormonereleas
hormon
receptor
ovarian
carcinoma
cxc
chemokin
receptor
receptor
multipl
tumor
type
twenti
type
cancer
exampl
breast
cancer
ovarian
cancer
glioma
pancreat
cancer
prostat
cancer
cervic
cancer
colon
carcinoma
renal
cancer
overexpress
steven
f
dowdi
group
took
advantag
signific
differ
express
tumor
cell
versu
healthi
tissu
construct
two
chimer
peptid
consist
receptor
ligand
bound
two
proven
transduc
anticanc
peptid
peptid
cyclindepend
kinas
cdk
antagonist
peptid
tatrxl
thu
anticanc
peptid
name
specif
direct
target
cell
overexpress
receptor
exert
toxic
effect
without
affect
nontumor
cell
screen
random
cyclic
phage
display
librari
perea
et
al
identifi
novel
cyclic
peptid
cwmsprhlgtc
abrog
phosphoryl
block
substrat
proteas
consid
critic
cancer
target
frequent
upregul
mani
human
tumor
direct
inhibit
shown
induc
apoptosi
vitro
therefor
phosphoryl
constitut
biochem
event
suitabl
target
develop
cancer
therapeut
fuse
tat
cpp
enhanc
cellular
uptak
system
induc
apoptosi
evidenc
rapid
caspas
activ
cellular
cytotox
varieti
tumor
cell
line
furthermor
direct
inject
mice
bear
day
solid
tumor
result
substanti
regress
tumor
mass
exampl
home
peptid
found
literatur
exampl
tltytw
peptid
specif
bind
collagen
iv
modifi
matrix
essenti
proteas
involv
process
angiogenesi
peptid
tumorspecif
inhibit
angiogenesi
vivo
assay
concentrationdepend
manner
also
significantli
reduc
endotheli
differenti
vitro
peptid
like
one
exampl
report
potent
candid
specif
home
wide
rang
tissu
combin
home
capac
cpp
may
allow
cpp
specif
direct
desir
locat
tao
jiang
et
al
took
advantag
matrix
metalloproteas
mmp
oversecret
cancer
cell
creat
target
drug
deliveri
system
mmp
extracellular
proteas
play
crucial
role
extracellular
matrix
degrad
tissu
invas
metastasi
cpp
known
enter
cell
result
cation
natur
interact
neg
charg
cell
surfac
follow
system
act
dormant
system
activ
upon
reach
desir
tissu
case
mmpoverexpress
cancer
tissu
posit
charg
cpp
initi
mask
polyanion
sequenc
upon
reach
tumor
tissu
overexpress
mmp
cleav
specif
sequenc
connect
cpp
anion
sequenc
figur
linker
cleav
acid
inhibitori
domain
drift
away
cation
cpp
free
carri
cargo
cell
interest
approach
benefit
extracellular
fate
occur
tumor
cell
proteas
sequenc
could
design
function
kind
tumor
diseas
treat
address
home
approach
base
peptid
sequenc
either
inher
cpp
sequenc
provid
adjac
home
peptid
chapter
focu
anoth
way
target
drug
deliveri
system
case
specif
achiev
drug
effect
desir
target
protein
known
guardian
genom
transcript
factor
encod
gene
human
regul
cell
cycl
function
tumor
suppressor
protein
frequent
mutat
gene
human
cancer
mutat
occur
central
dnabind
region
protein
domain
regul
ctermin
sequenc
previou
studi
report
addit
chemic
modifi
ctermin
peptid
aa
restor
vitro
sequencespecif
dna
bind
function
mutant
arg
furthermor
intranuclear
microinject
peptid
human
colon
cancer
cell
carri
endogen
mutant
restor
transcript
activ
report
construct
result
promis
bottleneck
cellular
uptak
chemic
modifi
ctermin
peptid
due
chemic
structur
capac
transloc
across
cell
membran
selivanova
et
al
design
ctermin
peptid
aa
fuse
antennapedia
cpp
facilit
cellular
uptak
demonstr
inhibit
growth
induct
apoptosi
colon
carcinoma
cell
mutant
fine
team
also
report
construct
induc
rapid
apoptosi
case
breast
cancer
cell
line
carri
endogen
mutat
peptid
toxic
nonmalign
breast
colon
cell
second
studi
team
show
chimer
peptid
induc
apoptosi
human
rat
glioma
cell
vitro
vivo
studi
signal
mechan
protein
act
cell
howev
perspect
concern
review
key
featur
system
combin
two
element
target
desir
cell
exert
pharmacolog
action
strategi
could
appli
futur
treatment
cancer
mutat
dnabind
domain
similar
approach
develop
dowdi
cowork
treatment
hiv
design
call
trojan
hors
strategi
kill
hivinfect
cell
exploit
hiv
proteas
case
combin
tat
cpp
protein
lead
new
strategi
kill
hivinfect
cell
leav
uninfect
cell
unharm
protein
use
modifi
procaspas
protein
transduc
infect
uninfect
cell
howev
modifi
endogen
cleavag
site
substitut
hiv
proteolyt
cleavag
site
thu
activ
hiv
proteas
infect
cell
therebi
result
apoptosi
wherea
uninfect
cell
remain
inact
zymogen
form
result
proof
concept
kind
intellig
drug
deliveri
system
could
appli
treat
diseas
caus
pathogen
proteas
fine
tune
proteolyt
cleavag
site
proteas
involv
diseas
like
hepat
c
viru
cytomegaloviru
malaria
solid
tumor
grow
environ
differ
complet
healthi
tissu
instanc
ph
surround
tumor
tissu
lower
usual
tumor
mass
low
result
hypox
condit
tumor
refractori
radiotherapi
anticanc
chemotherapi
tumor
cell
receiv
proper
amount
oxygen
tri
adapt
poor
environ
undergo
sever
chang
exampl
aerob
condit
express
hypoxiainduc
transcript
factor
bare
detect
upon
hypoxia
express
protein
greatli
increas
therebi
induc
activ
glucos
metabol
glucos
transport
produc
angiogen
growth
factor
also
involv
prevent
apoptosi
activ
gene
involv
metastasi
tumor
invas
given
data
could
consid
good
target
cancer
treatment
heterodim
form
subunit
subunit
sever
domain
particular
uniqu
oxygendepend
degrad
domain
odd
respons
regul
oxygendepend
degrad
protein
protein
stabil
hypox
environ
degrad
immedi
normal
oxygen
condit
object
follow
work
design
drug
abl
destroy
cell
masahiro
hiraoka
group
design
fusion
protein
drug
odd
stabil
fusion
protein
hypox
condit
normal
complex
degrad
odd
regulatori
mechan
depend
ubiquitinproteasom
system
locat
cell
cytoplasm
ptd
protein
transduct
domain
requir
transloc
fusion
protein
cell
case
transloc
system
cell
cytoplasm
use
tat
peptid
wide
report
transport
protein
cell
procaspas
function
part
complex
express
cell
stabl
activ
initi
caspas
activ
hypox
cell
thu
lead
cell
death
howev
cell
express
enough
odd
domain
lead
ubiquitin
degrad
construct
therebi
prevent
activ
thu
trigger
cell
death
final
fusion
protein
product
system
administ
mice
bear
human
pancreat
tumor
xenograft
suppress
tumor
growth
reduc
tumor
size
without
appar
side
effect
given
observ
specif
imag
target
activ
cell
feasibl
may
provid
novel
approach
treat
kind
difficult
cell
tumor
atpasedirect
molecular
chaperon
overse
control
protein
fold
qualiti
cellular
stress
respons
whose
client
protein
usual
signal
molecul
involv
cell
prolifer
cell
surviv
chaperon
thought
play
key
role
cancer
commonli
upregul
tumor
may
contribut
correct
fold
protein
synthes
stress
condit
therebi
help
cell
adapt
unfavor
environ
caus
tumor
growth
furthermor
survivin
essenti
regul
cell
prolifer
differenti
apoptosi
protein
overexpress
cancer
tissu
interact
order
maintain
correct
conform
follow
strategi
direct
inhibit
tumor
growth
progress
base
disrupt
interact
mean
target
drug
enter
cell
cpp
fortugno
et
al
identifi
survivin
sequenc
block
interact
survivin
vitro
work
sequenc
janet
plescia
cowork
succeed
minim
number
amino
acid
requir
block
interact
creat
sepherdin
molecul
interact
specif
also
capac
disrupt
complex
also
demonstr
intracellular
deliveri
sepherdin
induc
tumor
cell
death
purpos
fuse
n
termin
antennapedia
cpp
show
intern
hela
cell
demonstr
fusion
protein
abl
inhibit
interact
survivin
thu
inhibit
activ
pro
cancer
protein
also
bind
atp
pocket
therebi
destabil
client
protein
new
peptid
drug
capac
disrupt
two
crucial
cell
surviv
pathway
thu
becom
promis
drug
cancer
treatment
one
interest
part
work
capac
fusion
protein
induc
apoptosi
tumor
cell
main
object
target
cancer
therapi
achiev
group
sepherdin
reduc
viabil
nontransform
cell
howev
effect
kill
cancer
cell
fusion
protein
test
vivo
human
cancer
model
prostat
carcinoma
cell
grown
superfici
tumor
immunocompromis
mice
administr
sepherdin
tumor
palpabl
result
almost
complet
ablat
tumor
growth
affect
tissu
lung
spleen
liver
addit
sepherdin
kill
tumor
cell
far
rapidli
potent
antagonist
current
use
clinic
applic
consequ
sepherdin
consid
potenti
new
specif
drug
cancer
treatment
prion
diseas
also
refer
transmiss
spongiform
encephalopathi
tse
occur
human
anim
primarili
affect
central
nervou
system
hallmark
diseas
presenc
microscop
vacuol
brain
tissu
call
spongiform
degener
mean
tissu
deterior
develop
spongi
textur
presenc
abnorm
protein
call
scrapi
prion
protein
prpsc
prion
abnorm
prion
protein
diseas
involv
prpsc
unlik
known
infecti
diseas
believ
result
chang
conform
shape
normal
protein
call
cellular
prion
protein
prpc
present
larg
amount
brain
well
tissu
conform
prpsc
make
larg
resist
cellular
degrad
accumul
brain
consid
caus
neurodegener
death
interestingli
prpc
sever
domain
within
structur
residu
constitut
hydrophob
signal
sequenc
promot
entri
endoplasm
reticulum
er
usual
cleav
protein
reach
cell
surfac
usual
locat
lipid
raft
region
residu
posit
charg
form
one
two
independ
nuclear
local
signallik
segment
protein
basic
segment
prion
protein
describ
cpp
confer
solubl
hydrophob
signal
sequenc
prion
proteinderiv
cpp
prpcpp
compris
ntermin
signal
peptid
mous
residu
residu
bovin
prp
coupl
sequenc
respect
peptid
transport
hydrophob
cargo
across
cell
membran
lipid
raftdepend
macropinocytosi
mechan
lofgren
cowork
studi
capac
variou
cpp
prevent
prpc
convers
prpsc
team
found
peptid
deriv
nterminu
unprocess
prion
protein
antagon
prion
infect
work
vitro
use
cell
murin
neuron
hypothalam
cell
cell
infect
brain
homogen
thu
gener
chronic
prioninfect
cell
line
strongli
reduc
prpsc
express
prioninfect
cell
line
affect
prpc
express
noninfect
cell
research
done
studi
mechan
cpp
reduc
prpsc
express
howev
main
conclus
work
cpp
show
select
antiprion
activ
thu
open
avenu
develop
new
drug
prion
diseas
would
like
add
final
comment
section
review
describ
sever
strategi
cpp
sequenc
help
target
drug
reach
intracellular
compart
one
approach
involv
take
advantag
specif
proteas
overexpress
protein
howev
consid
specif
drug
mention
nucleic
acidbas
therapi
inevit
gene
therapi
maximum
express
target
drug
sequencespecif
variou
oligonucleotid
deriv
demonstr
remark
potenti
therapeut
applic
gene
regul
sirna
deliveri
current
focu
intens
research
effort
specif
bind
dicer
process
mrna
sequenc
therebi
alter
splice
site
lead
modifi
protein
may
use
treatment
diseas
howev
nucleic
acid
strongli
neg
charg
thu
unabl
cross
cell
membran
descript
coval
noncoval
strategi
report
cpp
help
sirna
penetr
cell
mani
group
demonstr
effect
downregul
gene
express
cppbase
sirna
deliveri
although
endosom
releas
continu
bottleneck
attempt
solv
cours
exampl
cppsirna
potenti
deliveri
strategi
review
follow
studi
field
nucleic
acid
deliveri
rapidli
improv
undergo
develop
fact
sever
chemic
modif
perform
increas
stabil
molecul
reduc
size
therebi
achiev
improv
bind
specif
instanc
peptid
nucleic
acid
pna
wide
use
phosphoramid
morpholino
oligonucleotid
pmo
clear
complex
conjug
oligonucleotid
cpp
effici
nontox
way
achiev
intracellular
deliveri
pharmaceut
agent
signific
biolog
activ
howev
main
bottleneck
deliveri
system
endosom
escap
research
effort
address
limit
step
section
focu
differ
way
direct
drug
deliveri
system
case
system
find
specif
locat
physic
chang
target
environ
thu
avoid
unspecif
uptak
cpp
domain
system
initi
hidden
reach
target
area
reach
desir
tissu
domain
woken
fulli
activ
promot
effici
intern
exampl
kind
strategi
describ
sethuraman
cowork
design
deliveri
system
name
smart
micellar
nanoplatform
take
advantag
low
ph
usual
found
tumor
environ
ph
result
lactic
acid
product
tumor
smart
micellar
nanoplatform
sever
compon
shown
figur
core
micel
compos
poli
llactic
acid
chemotherapeut
agent
incorpor
core
decor
polyethylen
glycol
peg
molecul
tat
attach
tat
molecul
electrostat
interact
polysulfonamid
psd
molecul
neg
charg
ph
thu
tat
molecul
shield
result
system
penetr
cell
system
reach
tumor
site
tat
micel
expos
surround
psd
molecul
becom
proton
lose
neg
charg
tat
help
target
drugload
micel
tumor
cell
cytotox
effect
occur
system
test
vitro
use
cell
rang
ph
micel
load
fluoresc
molecul
penetr
cell
acid
environ
therebi
prove
effect
intellig
system
nevertheless
test
approach
use
cancer
drug
vivo
assay
requir
evalu
specif
feasibl
torchilin
group
develop
anoth
strategi
target
tumor
cell
base
decreas
ph
tumor
tissu
work
liposom
pharmaceut
nanocarri
whose
surfac
hold
sever
moieti
figur
complex
reach
low
ph
environ
tat
peptid
hidden
longchain
peg
chain
also
hold
ligand
help
achiev
concentr
complex
target
cell
given
longchain
peg
attach
complex
mean
ph
labil
bond
hydrazon
bond
releas
complex
respons
lower
ph
media
tat
peptid
expos
interact
cell
surfac
therebi
contribut
intern
liposom
drug
hold
correct
function
system
confirm
vitro
nih
fibroblast
ph
ph
one
year
later
team
test
similar
drug
deliveri
system
vivo
purpos
phsensit
complex
administ
directli
tumor
tissu
intratumor
inject
work
repres
signific
step
toward
develop
intellig
drug
deliveri
system
strike
exampl
multifunct
drug
deliveri
system
one
approach
treat
primari
tumor
expos
high
temperatur
abl
therapi
use
temperatur
suffici
durat
directli
kill
cell
applic
mild
hyperthermia
clinic
develop
adjunct
variou
establish
cancer
treatment
radiotherapi
chemotherapi
follow
drug
deliveri
system
temperaturesensit
temperatur
use
enhanc
system
select
target
area
conjunct
region
local
hyperthermia
temperaturesensit
deliveri
system
enhanc
accumul
penetr
capac
heat
region
contain
malign
date
sever
temperaturesensit
peptid
describ
design
chang
structur
within
narrow
thermal
window
around
transit
differ
secondari
structur
produc
dramat
chang
peptid
properti
chang
revers
peptid
must
return
origin
state
upon
cool
normal
temperatur
gene
l
bidwel
drazen
raucher
provid
exampl
temperaturesensit
drug
deliveri
system
involv
cpp
design
elastinlik
polypeptid
valproglyxaagli
coupl
penetratin
peptid
deriv
helix
helixloophelix
region
cmyc
known
inhibit
cmyc
transcript
function
elastinlik
polym
solubl
aqueou
solut
transit
temperatur
tt
howev
temperatur
rais
tt
undergo
phase
transit
becom
insolubl
form
aggreg
case
heat
cell
show
notabl
greater
uptak
polypeptid
compar
peptid
nonheat
treat
cell
compar
nonrespons
control
peptid
observ
attribut
aggreg
take
place
high
temperatur
moreov
aggreg
effect
revers
also
show
cellular
effect
peptid
growth
rate
hela
cell
slow
construct
therebi
demonstr
potenti
peptid
futur
treatment
tumor
vivo
mani
favor
properti
elp
sequenc
make
good
candid
drug
deliveri
vector
prove
thermorespons
properti
solubl
normal
temperatur
addit
express
bacteria
larg
amount
elp
easili
purifi
also
genet
modifi
order
insert
cellpenetr
sequenc
therapeut
peptid
protein
appli
high
temperatur
tumor
mass
could
theoret
lead
enhanc
concentr
deliveri
system
region
therebi
minim
side
effect
improv
cancer
therapi
follow
exampl
target
tool
system
consist
lowvoltag
electr
puls
author
studi
prove
intern
efficaci
tat
peptid
coupl
glycogen
synthas
highli
enhanc
applic
lowvoltag
puls
depend
cell
line
without
harm
cell
studi
preliminari
howev
demonstr
anoth
way
target
system
cell
studi
could
appli
lowvoltag
puls
region
contain
malign
cell
order
increas
drug
deliveri
wish
make
refer
final
strategi
drug
deliveri
system
take
advantag
physic
characterist
present
area
directli
target
case
physic
target
inher
properti
diseas
deliveri
system
topic
appli
affect
area
system
use
treat
inflammatori
skin
diseas
drug
consist
polyarginin
cpp
conjug
cyclosporin
csa
skin
diseas
usual
treat
system
administr
drug
may
involv
side
effect
topic
administ
drug
could
use
treatment
skin
diseas
howev
poor
absorpt
result
lack
skin
permeabl
continu
main
drawback
approach
studi
use
cpp
enhanc
drug
absorpt
skin
oral
administ
csa
highli
effect
wide
rang
inflammatori
skin
diseas
psoriasi
atop
dermat
csa
conjug
heptam
arginin
linker
design
releas
activ
drug
physiolog
ph
within
tissu
approach
facilit
penetr
csa
mous
human
skin
solubl
csa
enhanc
water
effect
reduc
inflamm
observ
observ
demonstr
efficaci
cpp
enhanc
skin
absorpt
agent
thu
open
new
avenu
field
skin
diseas
treatment
fact
treatment
current
clinic
trial
phase
trial
success
literatur
provid
exampl
cpp
enhanc
drug
absorpt
appli
local
instanc
mccusker
cowork
describ
origin
strategi
treatment
allerg
airway
diseas
sought
inhibit
protein
key
point
target
treatment
diseas
involv
regul
airway
inflamm
mucu
product
airway
hyperrespons
howev
target
complic
intracellular
locat
group
design
specif
inhibitor
peptid
bound
tat
cpp
deliv
directli
lung
murin
model
inhibit
aginduc
inflammatori
respons
therebi
inhibit
chemokin
express
mucu
product
eosinophil
influx
lung
local
applic
diseas
treatment
consist
cpp
coupl
specif
drug
promis
new
therapeut
approach
treatment
diseas
case
allerg
rhiniti
asthma
last
section
review
address
complex
drug
deliveri
system
target
specif
locat
includ
cpp
increas
cellular
uptak
system
exampl
previous
describ
phsensit
drug
deliveri
system
system
design
vp
torchilin
group
heckl
cowork
publish
new
strategi
visual
prostat
cancer
use
magnet
reson
imag
mri
object
develop
novel
mri
contrast
agent
capac
accumul
specif
tumor
cell
rel
long
period
gadolinium
commonli
use
extracellular
imag
agent
mri
suitabl
intracellular
imag
assay
use
intracellular
agent
mean
microinject
cell
conjug
cpp
tat
case
report
apart
lack
specif
main
problem
strategi
rapid
influx
efflux
particl
achiev
longer
perman
cell
construct
bound
pna
connect
antennapedia
cpp
pna
direct
cmyc
mrna
mrna
highli
express
tumor
cell
hypothes
pna
coupl
cmyc
mrna
would
increas
life
therebi
provid
agent
specif
mri
imag
verifi
increas
intern
complex
basi
presenc
cpp
complex
transport
cell
membran
use
cpp
may
provid
altern
approach
vivo
vitro
applic
also
observ
vitro
hela
cell
vivo
prostat
adenocarcinoma
particl
retain
longer
antennapedia
particl
without
cmyc
pna
author
cautiou
interpret
result
directli
relat
presenc
complementari
pna
highli
express
protein
cell
longer
retent
time
particl
insid
cell
suggest
longer
retent
complex
may
due
given
properti
tumor
membran
cell
thu
slower
efflux
cmycspecif
complex
would
independ
pna
design
although
research
field
requir
promis
result
specif
intracellular
imag
tumor
liposom
wide
studi
drug
deliveri
treatment
mani
diseas
cancer
hiv
addit
cation
liposom
conjug
dna
lipoplex
also
investig
preclin
clinic
trial
vitro
transfect
efficaci
compar
viral
vector
main
drawback
system
lack
specif
despit
consider
potenti
approach
still
requir
develop
torchilin
group
recent
describ
new
strategi
target
lipoplex
ischem
cell
aim
lipoplex
treat
myocardi
ischemia
myocardi
infarct
two
diseas
gene
therapi
still
hold
huge
potenti
enough
data
support
overexpress
gene
cardiac
fiber
protect
ischem
injuri
instanc
overexpress
fibroblast
growth
heart
increas
resist
ischem
injuri
isol
mous
heart
model
shortli
studi
gene
transfer
hsp
report
protect
cardiac
function
ischemia
reperfus
improv
myocardi
perfus
function
recoveri
also
observ
gene
transfer
vegf
fgf
hgf
given
inform
direct
gene
deliveri
cardiac
cell
would
good
approach
treat
diseas
ko
cowork
design
new
multifunct
drug
deliveri
system
proof
concept
direct
gene
deliveri
cardiac
cell
system
consist
cation
liposom
carri
pdna
encod
green
fluoresc
protein
gfp
modifi
tat
cpp
increas
cellular
uptak
highli
specif
antimyosin
monoclon
antibodi
mab
antibodi
demonstr
excel
capac
recogn
bind
ischem
cell
damag
plasma
membran
intracellular
myosin
becom
expos
extracellular
space
thu
lipoplex
concentr
desir
area
afterward
intern
cell
therebi
allow
gene
transfer
despit
solubl
problem
usual
associ
intraven
inject
lipoplex
system
describ
increas
solubl
addit
molecul
system
system
test
vitro
cell
cultur
rat
cardiomyocyt
vivo
emi
model
rat
show
preferenti
accumul
construct
ischem
area
infarct
rat
heart
promis
result
target
deliveri
gene
howev
would
interest
see
effect
load
therapeut
gene
instead
gfp
nevertheless
field
undergo
certain
improv
near
futur
kind
multicompon
system
expect
establish
effect
drug
deliveri
system
treatment
mani
diseas
follow
strategi
use
human
serum
albumin
hsa
natur
carrier
polym
hsa
mani
advantag
long
circul
time
high
biocompat
high
biodegrad
possibl
easili
chemic
modifi
case
drug
kinas
inhibitor
target
kinas
current
strategi
wide
studi
treatment
chronic
inflammatori
diseas
kinas
respons
activ
endotheli
cell
diseas
cell
turn
secret
cytokin
chemokin
promot
leukocyt
recruit
infiltr
system
also
includ
cyclic
rgdfk
peptid
known
bind
high
affin
specif
integrin
previous
defin
cpp
peptid
confer
select
penetr
properti
complex
integrin
overexpress
angiogen
endothelium
part
patholog
chronic
inflammatori
diseas
rheumatoid
arthriti
crohn
diseas
nontox
drug
deliveri
system
interf
inflammatori
signal
cascad
vitro
therebi
show
potenti
treatment
inflammatori
diseas
one
year
later
group
publish
anoth
hasbas
drug
deliveri
system
also
carri
rgd
cpp
target
angiogen
endotheli
tumor
cell
case
auristatin
anticanc
drug
vitro
result
encourag
case
studi
requir
evalu
suitabl
system
vivo
applic
sever
exampl
drug
deliveri
system
cpp
use
increas
penetr
system
cell
case
specif
system
sirna
act
cell
express
amount
mrna
complementari
sirna
exampl
review
one
major
drawback
field
drug
deliveri
way
bypass
cell
membran
mani
potenti
therapeut
agent
nucleic
acid
protein
hydrophil
drug
use
unabl
enter
cell
exert
therapeut
action
sever
approach
develop
overcom
problem
exampl
viral
vector
highli
effici
intracellular
deliveri
disadvantag
induc
specif
immun
respons
quit
complic
structur
develop
requir
elucid
biolog
underli
interact
addit
vivo
transduct
effici
viral
vehicl
requir
improv
develop
nonvir
vehicl
repres
easier
less
expens
safer
altern
viral
vector
nonvir
vehicl
simpler
system
fulli
control
mainli
nonimmunogen
howev
limit
low
transfect
effici
insuffici
distribut
target
cell
vivo
overcom
one
import
featur
improv
field
nonvir
deliveri
system
cell
specif
mani
nonvir
vector
avail
drug
gene
deliveri
recent
differ
effort
direct
chemic
modifi
viral
vector
propos
strategi
chemoviru
chimer
system
alreadi
year
sinc
frankel
pabo
describ
tat
mani
cellpenetr
sequenc
report
mani
other
improv
addit
capac
sequenc
deliv
wide
varieti
cargo
cell
small
peptid
protein
dna
sirna
pna
organ
moieti
vivo
vitro
demonstr
howev
main
drawback
cpp
despit
good
cellpenetr
capac
fact
nonimmunogen
bare
toxic
show
cell
select
cellular
uptak
mechan
cpp
still
fulli
understood
consensu
first
contact
cpp
cell
surfac
occur
electrostat
interact
cation
peptid
neg
charg
cell
surfac
therefor
lack
specif
major
issu
solv
cpp
use
drug
deliveri
review
attempt
summar
exampl
novel
drug
deliveri
system
system
share
two
main
properti
target
specif
cell
tissu
structur
carri
cpp
mani
strategi
describ
prove
success
vivo
experi
therefor
numer
clinic
preclin
studi
cppbase
deliveri
strategi
current
evalu
cyclosporinepolyarginin
conjug
topic
treatment
psoriasi
oral
administr
cyclosporin
csa
effect
broad
rang
inflammatori
skin
diseas
includ
psoriasi
howev
system
administr
molecul
consider
side
effect
nephrotox
topic
applic
csa
would
minim
side
effect
would
contribut
treatment
diseas
topic
applic
csa
show
low
effect
due
poor
absorpt
howev
conjug
cpp
heptaarginin
csa
linker
design
releas
activ
compound
tissu
ph
enhanc
topic
absorpt
inhibit
cutan
inflamm
enter
phase
ii
trial
cellgat
inc
cppbase
strategi
drug
deliveri
current
also
undergo
clinic
trial
instanc
test
kai
pharmaceut
tatprotein
kinas
c
inhibitor
peptid
modul
protein
kinas
c
acut
myocardi
infarct
cerebr
ischemia
peptid
enter
phase
ii
avi
biopharma
work
clinic
develop
cpp
vivo
steric
block
splice
correct
use
acid
space
oligoarginin
rahxr
consist
morpholino
oligo
conjug
mention
cpp
rxr
xb
cpp
goal
construct
prevent
eventu
blockag
transplant
vein
cardiovascular
bypass
surgeri
sever
compani
eg
traversa
inc
panom
inc
current
evalu
cpp
preclin
clinic
trial
addit
great
number
molecul
conjug
cpp
alreadi
preclin
phase
get
optim
futur
clinic
trial
summari
cpp
realiti
drug
deliveri
induc
cell
select
cppmediat
strategi
next
step
improv
current
drug
deliveri
system
order
decreas
side
effect
amount
drug
requir
achiev
given
intracellular
target
innov
rang
strategi
describ
review
may
soon
enter
clinic
trial
may
contribut
further
field
drug
deliveri
